MK-1045

MK-1045 (CN-201, CN201) is an investigational agent whose form is not stated in the registry developed by Merck Sharp & Dohme and MSD R&D (China). Its target is CD19 (the sponsor names CD19). The sponsor states: MK-1045 is described as a novel immunotherapy, given intravenously, being compared with blinatumomab in relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07570173 (A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukaemia (MK-1045-005)) and NCT07634471 (A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)), in acute lymphoblastic leukaemia, follicular lymphoma, hodgkin lymphoma and diffuse large B-cell lymphoma. The largest, NCT07634471, plans to enrol 960 participants with primary completion expected 2032-07-23. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.